AI In Pathology Market Size, Share & Trends Analysis Report By Component (Software, Hardware), By Technology (Machine Learning, Computer Vision-based Image Analysis), By Application (Disease Diagnosis & Classification), By End Use, By Region, And Segment
Description
AI In Pathology Market Summary
The global AI in pathology market size was estimated at USD 134.57 million in 2024 and is projected to reach USD 1,151.55 million by 2033, growing at a CAGR of 27.18% from 2025 to 2033. Growing demand for precision medicine, rising prevalence of chronic diseases, technological advancements are significant factors contributing to market growth.
Moreover, the growing digitization of pathological infrastructure, supportive regulatory progress, and industry partnerships are strengthening the market environment. The growing demand for precision medicine is one of the significant drivers of AI in pathology market. AI facilitates tailored treatments by integrating histopathological image analysis with genomic data to provide more precise disease subtyping and prognosis. For instance, in July 2025, LG AI Research unveiled its upgraded pathology AI model, EXAONE Path 2.0, to enhance cancer diagnosis and drug development. The system combines analysis of both entire slide images and smaller patches to avoid feature collapse and preserve contextual information. Trained on multi-omics data, including DNA, RNA, and whole slide pathology images, the model analyzes genetic mutations, gene expression, and subtle tissue changes with 78.4% prediction accuracy.
In addition, growing funding for AI research and healthcare digital transformation programs, alongside rising adoption of telepathology, support the deployment of AI tools on a large scale. For instance, in March 2025, Proscia secured USD 50 million in funding to accelerate the adoption of its AI-powered Concentriq platform, an AI-driven pathology solution, to integrate more AI capabilities and leverage partnerships with OEMs like Agilent Technologies and Siemens Healthineers.
Workflow optimization and operational efficiency in laboratories also significantly fuel the adoption of AI pathology solutions. AI-driven automation of routine tasks such as tissue segmentation, cell counting, and measurement reduces manual labor and human error, allowing pathologists to devote more time to complex cases. For instance, in January 2025, Owkin unveiled new insights into digital pathology and AI solutions, highlighting challenges such as rising pathologist burnout due to workload and diagnostic complexity. Their AI diagnostics support quick interpretation of whole slide images, biomarker screening, and patient outcome predictions to enable precision oncology.
Furthermore, industry partnerships are strengthening the market environment. Pharmaceutical companies are collaborating with AI developers to incorporate digital pathology into clinical trials and drug development. For instance, in April 2025, Precision for Medicine and PathAI announced a strategic collaboration to develop novel AI technologies and integrate PathAI’s advanced digital pathology capabilities into Precision for Medicine’s clinical trial and biospecimen operations. Precision for Medicine is expected to leverage PathAI’s AISight image management system and AI algorithms to enhance biospecimen analysis workflows with quality control steps, improving data consistency and reliability.
Global AI In Pathology Market Segmentation
This report forecasts, revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented global AI in pathology market report based on component, technology, application, end use, and region.
The global AI in pathology market size was estimated at USD 134.57 million in 2024 and is projected to reach USD 1,151.55 million by 2033, growing at a CAGR of 27.18% from 2025 to 2033. Growing demand for precision medicine, rising prevalence of chronic diseases, technological advancements are significant factors contributing to market growth.
Moreover, the growing digitization of pathological infrastructure, supportive regulatory progress, and industry partnerships are strengthening the market environment. The growing demand for precision medicine is one of the significant drivers of AI in pathology market. AI facilitates tailored treatments by integrating histopathological image analysis with genomic data to provide more precise disease subtyping and prognosis. For instance, in July 2025, LG AI Research unveiled its upgraded pathology AI model, EXAONE Path 2.0, to enhance cancer diagnosis and drug development. The system combines analysis of both entire slide images and smaller patches to avoid feature collapse and preserve contextual information. Trained on multi-omics data, including DNA, RNA, and whole slide pathology images, the model analyzes genetic mutations, gene expression, and subtle tissue changes with 78.4% prediction accuracy.
In addition, growing funding for AI research and healthcare digital transformation programs, alongside rising adoption of telepathology, support the deployment of AI tools on a large scale. For instance, in March 2025, Proscia secured USD 50 million in funding to accelerate the adoption of its AI-powered Concentriq platform, an AI-driven pathology solution, to integrate more AI capabilities and leverage partnerships with OEMs like Agilent Technologies and Siemens Healthineers.
Workflow optimization and operational efficiency in laboratories also significantly fuel the adoption of AI pathology solutions. AI-driven automation of routine tasks such as tissue segmentation, cell counting, and measurement reduces manual labor and human error, allowing pathologists to devote more time to complex cases. For instance, in January 2025, Owkin unveiled new insights into digital pathology and AI solutions, highlighting challenges such as rising pathologist burnout due to workload and diagnostic complexity. Their AI diagnostics support quick interpretation of whole slide images, biomarker screening, and patient outcome predictions to enable precision oncology.
Furthermore, industry partnerships are strengthening the market environment. Pharmaceutical companies are collaborating with AI developers to incorporate digital pathology into clinical trials and drug development. For instance, in April 2025, Precision for Medicine and PathAI announced a strategic collaboration to develop novel AI technologies and integrate PathAI’s advanced digital pathology capabilities into Precision for Medicine’s clinical trial and biospecimen operations. Precision for Medicine is expected to leverage PathAI’s AISight image management system and AI algorithms to enhance biospecimen analysis workflows with quality control steps, improving data consistency and reliability.
Global AI In Pathology Market Segmentation
This report forecasts, revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented global AI in pathology market report based on component, technology, application, end use, and region.
- Component Outlook (Revenue, USD Million, 2021 - 2033)
- Software
- Image Analysis & Pattern Recognition
- Predictive Analytics Tools
- Workflow Automation Software
- Diagnostic Decision Support
- Hardware
- Whole Slide Imaging (WSI) Scanners
- Digital Pathology Systems
- AI-Enabled Microscopes
- Service
- Implementation & Integration
- Consulting & Training
- Managed AI Services
- Maintenance & Support
- Technology Outlook (Revenue, USD Million, 2021 - 2033)
- Machine Learning (ML)
- Deep Learning
- Convolutional Neural Networks (CNNS)
- Generative Adversarial Networks (GANS)
- Recurrent Neural Networks (RNNS)
- Other Neural Networks
- Natural Language Processing (NLP)
- Computer Vision-based Image Analysis
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Disease Diagnosis & Classification
- Prognostic & Predictive Biomarker Discovery
- Digital Slide Image Analysis
- Clinical Workflow Optimization
- Drug Discovery & Research Pathology
- Tissue & Cell Analysis
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals & Diagnostic Laboratories
- Life Sciences Companies
- Research Institutes & Academic Centers
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
100 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
- 1.2.1. Component Segment
- 1.2.2. Technology Segment
- 1.2.3. Application Segment
- 1.2.4. End Use
- 1.3. Information analysis
- 1.3.1. Market formulation & data visualization
- 1.4. Data validation & publishing
- 1.5. Information Procurement
- 1.5.1. Primary Research
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Model
- 1.9. Total Market: CAGR Calculation
- 1.10. Objectives
- 1.10.1. Objective 1
- 1.10.2. Objective 2
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Insights Landscape
- Chapter 3. AI in Pathology Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Rising demand for accurate and early disease detection
- 3.2.1.2. Technological advancements in machine learning, natural language processing, and computer vision
- 3.2.1.3. Increasing government initiatives and regulatory support
- 3.2.2. Market restraint analysis
- 3.2.2.1. Data security and privacy concerns
- 3.2.2.2. High costs of advanced devices
- 3.2.3. Market opportunity analysis
- 3.2.4. Market challenges analysis
- 3.3. AI in Pathology Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.2.4. Environmental Landscape
- 3.3.2.5. Legal Landscape
- 3.3.2.6. Social Landscape
- 3.4. Case Study Insights
- 3.4.1. Building tools for machine learning and artificial intelligence in computational pathology
- 3.5. Investment & funding scenario
- 3.6. Technology Analysis: Key Use Cases and Application
- 3.6.1. Machine Learning (ML)/Deep Learning
- 3.6.2. Natural Language Processing (NLP)
- 3.6.3. Computer Vision-based Image Analysis
- Chapter 4. AI In Pathology Market: Component Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global AI in Pathology Market Component Movement Analysis
- 4.3. Global AI in Pathology Market Size & Trend Analysis, by Component, 2021 to 2033 (USD Million)
- 4.4. Software
- 4.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.4.2. Image Analysis & Pattern Recognition
- 4.4.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.4.3. Predictive Analytics Tools
- 4.4.3.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.4.4. Workflow Automation Software
- 4.4.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.4.5. Diagnostic Decision Support
- 4.4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.5. Hardware
- 4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.5.2. Whole Slide Imaging (WSI) Scanners
- 4.5.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.5.3. Digital Pathology Systems
- 4.5.3.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.5.4. AI-Enabled Microscopes
- 4.5.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.6. Services
- 4.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.6.2. Implementation & Integration
- 4.6.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.6.3. Consulting & Training
- 4.6.3.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.6.4. Managed AI Services
- 4.6.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 4.6.5. Maintenance & Support
- 4.6.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- Chapter 5. AI In Pathology Market: Technology Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global AI in Pathology Market Technology Movement Analysis
- 5.3. Global AI in Pathology Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
- 5.4. Machine Learning Algorithms
- 5.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.4.2. Deep learning
- 5.4.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.4.2.2. Convolutional Neural Networks (CNNS)
- 5.4.2.2.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.4.2.3. Generative Adversarial Networks (GANS)
- 5.4.2.3.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.4.2.4. Recurrent Neural Networks (RNNS)
- 5.4.2.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.4.2.5. Other Neural Networks
- 5.4.2.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.5. Natural Language Processing (NLP)
- 5.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 5.6. Computer Vision-based Image Analysis
- 5.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- Chapter 6. AI In Pathology Market: Application Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global AI in Pathology Market Application Movement Analysis
- 6.3. Global AI in Pathology Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 6.4. Disease Diagnosis & Classification
- 6.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.5. Prognostic & Predictive Biomarker Discovery
- 6.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.6. Digital Slide Image Analysis
- 6.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.7. Clinical Workflow Optimization
- 6.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.8. Drug Discovery & Research Pathology
- 6.8.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.9. Tissue & Cell Analysis
- 6.9.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 6.10. Others
- 6.10.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- Chapter 7. AI In Pathology Market: End Use Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Global AI in Pathology Market End Use Movement Analysis
- 7.3. Global AI in Pathology Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
- 7.4. Hospitals & Diagnostic Laboratories
- 7.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.5. Life Sciences Companies
- 7.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.6. Research Institutes & Academic Centers
- 7.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- 7.7. Others
- 7.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
- Chapter 8. AI In Pathology Market: Regional Estimates & Trend Analysis
- 8.1. Regional Market Share Analysis, 2024 & 2033
- 8.2. Regional Market Dashboard
- 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
- 8.4. North America
- 8.4.1. U.S.
- 8.4.1.1. Key country dynamics
- 8.4.1.2. Regulatory framework
- 8.4.1.3. Competitive scenario
- 8.4.1.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.4.2. Canada
- 8.4.2.1. Key country dynamics
- 8.4.2.2. Regulatory framework
- 8.4.2.3. Competitive scenario
- 8.4.2.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.4.3. Mexico
- 8.4.3.1. Key country dynamics
- 8.4.3.2. Regulatory framework
- 8.4.3.3. Competitive scenario
- 8.4.3.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.5. Europe
- 8.5.1. UK
- 8.5.1.1. Key country dynamics
- 8.5.1.2. Regulatory framework
- 8.5.1.3. Competitive scenario
- 8.5.1.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.5.2. Germany
- 8.5.2.1. Key country dynamics
- 8.5.2.2. Regulatory framework
- 8.5.2.3. Competitive scenario
- 8.5.2.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.5.3. France
- 8.5.3.1. Key country dynamics
- 8.5.3.2. Regulatory framework
- 8.5.3.3. Competitive scenario
- 8.5.3.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.5.4. Italy
- 8.5.4.1. Key country dynamics
- 8.5.4.2. Regulatory framework
- 8.5.4.3. Competitive scenario
- 8.5.4.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.5.5. Spain
- 8.5.5.1. Key country dynamics
- 8.5.5.2. Regulatory framework
- 8.5.5.3. Competitive scenario
- 8.5.5.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.5.6. Norway
- 8.5.6.1. Key country dynamics
- 8.5.6.2. Regulatory framework
- 8.5.6.3. Competitive scenario
- 8.5.6.4. Norway market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.5.7. Sweden
- 8.5.7.1. Key country dynamics
- 8.5.7.2. Regulatory framework
- 8.5.7.3. Competitive scenario
- 8.5.7.4. Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.5.8. Denmark
- 8.5.8.1. Key country dynamics
- 8.5.8.2. Regulatory framework
- 8.5.8.3. Competitive scenario
- 8.5.8.4. Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.1.1. Key country dynamics
- 8.6.1.2. Regulatory framework
- 8.6.1.3. Competitive scenario
- 8.6.1.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6.2. China
- 8.6.2.1. Key country dynamics
- 8.6.2.2. Regulatory framework
- 8.6.2.3. Competitive scenario
- 8.6.2.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6.3. India
- 8.6.3.1. Key country dynamics
- 8.6.3.2. Regulatory framework
- 8.6.3.3. Competitive scenario
- 8.6.3.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6.4. Australia
- 8.6.4.1. Key country dynamics
- 8.6.4.2. Regulatory framework
- 8.6.4.3. Competitive scenario
- 8.6.4.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6.5. South Korea
- 8.6.5.1. Key country dynamics
- 8.6.5.2. Regulatory framework
- 8.6.5.3. Competitive scenario
- 8.6.5.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.6.6. Thailand
- 8.6.6.1. Key country dynamics
- 8.6.6.2. Regulatory framework
- 8.6.6.3. Competitive scenario
- 8.6.6.4. Thailand market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.7. Latin America
- 8.7.1. Brazil
- 8.7.1.1. Key country dynamics
- 8.7.1.2. Regulatory framework
- 8.7.1.3. Competitive scenario
- 8.7.1.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.7.2. Argentina
- 8.7.2.1. Key country dynamics
- 8.7.2.2. Regulatory framework
- 8.7.2.3. Competitive scenario
- 8.7.2.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.8. MEA
- 8.8.1. South Africa
- 8.8.1.1. Key country dynamics
- 8.8.1.2. Regulatory framework
- 8.8.1.3. Competitive scenario
- 8.8.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.8.2. Saudi Arabia
- 8.8.2.1. Key country dynamics
- 8.8.2.2. Regulatory framework
- 8.8.2.3. Competitive scenario
- 8.8.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.8.3. UAE
- 8.8.3.1. Key country dynamics
- 8.8.3.2. Regulatory framework
- 8.8.3.3. Competitive scenario
- 8.8.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
- 8.8.4. Kuwait
- 8.8.4.1. Key country dynamics
- 8.8.4.2. Regulatory framework
- 8.8.4.3. Competitive scenario
- 8.8.4.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)
- Chapter 9. Competitive Landscape
- 9.1. Company/Competition Categorization
- 9.2. Strategy Mapping
- 9.3. Company Market Position Analysis, 2024
- 9.4. Company Profiles/Listing
- 9.4.1. Leica Biosystems Nussloch GmbH (subsidiary of Danaher)
- 9.4.1.1. Company overview
- 9.4.1.2. Financial performance
- 9.4.1.3. Product benchmarking
- 9.4.1.4. Strategic initiatives
- 9.4.2. Koninklijke Philips N.V.
- 9.4.2.1. Company overview
- 9.4.2.2. Financial performance
- 9.4.2.3. Product benchmarking
- 9.4.2.4. Strategic initiatives
- 9.4.3. F. Hoffmann-La Roche Ltd.
- 9.4.3.1. Company overview
- 9.4.3.2. Financial performance
- 9.4.3.3. Product benchmarking
- 9.4.3.4. Strategic initiatives
- 9.4.4. PathAI
- 9.4.4.1. Company overview
- 9.4.4.2. Financial performance
- 9.4.4.3. Product benchmarking
- 9.4.4.4. Strategic initiatives
- 9.4.5. Proscia Inc.
- 9.4.5.1. Company overview
- 9.4.5.2. Financial performance
- 9.4.5.3. Product benchmarking
- 9.4.5.4. Strategic initiatives
- 9.4.6. Aiforia/ Aiforia Technologies PLC
- 9.4.6.1. Company overview
- 9.4.6.2. Financial performance
- 9.4.6.3. Product benchmarking
- 9.4.6.4. Strategic initiatives
- 9.4.7. Ibex Medical Analytics
- 9.4.7.1. Company overview
- 9.4.7.2. Financial performance
- 9.4.7.3. Product benchmarking
- 9.4.7.4. Strategic initiatives
- 9.4.8. Mindpeak GmbH
- 9.4.8.1. Company overview
- 9.4.8.2. Financial performance
- 9.4.8.3. Product benchmarking
- 9.4.8.4. Strategic initiatives
- 9.4.9. Owkin, Inc.
- 9.4.9.1. Company overview
- 9.4.9.2. Financial performance
- 9.4.9.3. Product benchmarking
- 9.4.9.4. Strategic initiatives
- 9.4.10. Tempus AI
- 9.4.10.1. Company overview
- 9.4.10.2. Financial performance
- 9.4.10.3. Product benchmarking
- 9.4.10.4. Strategic initiatives
- 9.4.11. Indica Labs, LLC.
- 9.4.11.1. Company overview
- 9.4.11.2. Financial performance
- 9.4.11.3. Product benchmarking
- 9.4.11.4. Strategic initiatives
- 9.4.12. Qritive
- 9.4.12.1. Company overview
- 9.4.12.2. Financial performance
- 9.4.12.3. Product benchmarking
- 9.4.12.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.